Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of...

por Kastelein, John J. P., Robinson, Jennifer G., Farnier, Michel, Krempf, Michel, Langslet, Gisle, Lorenzato, Christelle, Gipe, Daniel A., Baccara-Dinet, Marie T.
Publicado 2014

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

por Ahmad, Zahid, Banerjee, Poulabi, Hamon, Sara, Chan, Kuo-Chen, Bouzelmat, Aurelie, Sasiela, William J., Pordy, Robert, Mellis, Scott, Dansky, Hayes, Gipe, Daniel A., Dunbar, Richard L.
Publicado 2019

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report

por Reeskamp, Laurens F., Millar, John S., Wu, Liya, Jansen, Hans, van Harskamp, Dewi, Schierbeek, Henk, Gipe, Daniel A., Rader, Daniel J., Dallinga-Thie, Geesje M., Hovingh, G. Kees, Cuchel, Marina
Publicado 2021

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patien...

por Banerjee, Poulabi, Chan, Kuo-Chen, Tarabocchia, Michel, Benito-Vicente, Asier, Alves, Ana C., Uribe, Kepa B., Bourbon, Mafalda, Skiba, Paul J., Pordy, Robert, Gipe, Daniel A., Gaudet, Daniel, Martin, Cesar
Publicado 2019

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

por Kastelein, John J.P., Ginsberg, Henry N., Langslet, Gisle, Hovingh, G. Kees, Ceska, Richard, Dufour, Robert, Blom, Dirk, Civeira, Fernando, Krempf, Michel, Lorenzato, Christelle, Zhao, Jian, Pordy, Robert, Baccara-Dinet, Marie T., Gipe, Daniel A., Geiger, Mary Jane, Farnier, Michel
Publicado 2015